Multidrug Resistance in Breast Cancer--Is the Jury in Yet?
Open Access
- 2 July 1997
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 89 (13) , 902-903
- https://doi.org/10.1093/jnci/89.13.902
Abstract
The term “multidrug resistance” has come to mean different things to different people. Initially, it was coined to describe the laboratory phenomenon of cross-resistance to various natural products, and this phenomenon was later found to relate to increased expression of P-glycoprotein (gp170) ( 1 ). Since then, many laboratory scientists and some clinicians have mistakenly assumed that the clinical observation of drug resistance to a wide range of cytotoxic agents has the same basis. Are the two in fact related? In this issue of the Journal, Trock et al. ( 2 ) have conducted an exhaustive review of the literature in an attempt to answer this question as it relates to breast cancer. There has been a plethora of studies with widely varying conclusions, and an attempt to distill them into a single review article is indeed praiseworthy. But there are problems.Keywords
This publication has 6 references indexed in Scilit:
- Multidrug Resistance in Breast Cancer: a Meta-analysis of MDR1/gp170 Expression and Its Possible Functional SignificanceJNCI Journal of the National Cancer Institute, 1997
- p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical studyBritish Journal of Cancer, 1997
- P-Glycoprotein — A Marker of Cancer-Cell BehaviorNew England Journal of Medicine, 1995
- Decreased Mutation Rate for Cellular Resistance to Doxorubicin and Suppression of mdrl Gene Activation by the Cyclosporin PSC 833JNCI Journal of the National Cancer Institute, 1995
- Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53Science, 1992
- Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell LinesScience, 1983